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ABSTRACT 
Objective: Cases of varicella pneumonitis were reviewed to 
examine the effects of acyclovir therapy on outcome. 
Methods: A retrospective chart review was done of all admis- 
sions of adults to two hospitals, between 1985 and 1995, 
because of complications of chickenpox. 
Results: Fifteen patients were hospitalized for varicella pneu- 
monitis during this period. No patient had a history of chick- 
enpox as a child; all had a recent history (within 2-4 weeks prior 
to admission) of exposure to chickenpox in their family or neigh- 
borhood and developed respiratory symptoms 1 to 4 days after 
the appearance of the rash. Twelve patients (80%) had a his- 
tory of cigarette smoking, and seven patients had a platelet 
count below the normal range. All patients were treated with 
intravenous acyclovir within 24 hours of admission, and all but 
one sun/ived and were discharged from the hospital without 
comorbid conditions. The one mortality was attributed to bac- 
terial superinfection. 
Conclusions: Acyclovir treatment may be of benefit for varicella 
pneumonitis, but no controlled trial has been performed to 
definitively answer this question. 
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Varicella is usually a benign infection of childhood. In 
adults, varicella is more frequently associated with com- 
plications (especially respiratory and neurologic compli- 
cations). Of these, varicella pneumonitis is the most 
common, and it has been reported to be associated with 
the highest mortality.’ Scattered reports describe the use 
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of the antiviral acyclovir for the treatment of life-threat- 
ening disease in healthy adults and in pregnancy.2l3 This 
report describes the authors’ experience over the past 
10 years with 15 patients with varicella pneumonitis. The 
medical histories, clinic presentations, laboratory and radi- 
ologic features, and outcomes with acyclovir treatment 
were reviewed. 
METHODS 
The records of patients admitted to Strong Memorial Hos- 
pital or St. Mary’s Hospital, Rochester, New York, from 
1985 to 1995, with varicella and chest roentgenographic 
evidence of pneumonitis were included. The study was 
limited to immunocompetent and nonpregnant patients. 
Strong Memorial Hospital is a 750-bed tertiary care refer- 
ral hospital and is the primary teaching hospital of The 
University of Rochester School of Medicine and Dentistry. 
St. Mary’s Hospital is a 240-bed community teaching hos- 
pital affiliated with The University of Rochester School 
of Medicine and Dentistry. All medical records were 
reviewed to obtain information on clinical features and 
the results of the laboratory investigation, treatment, and 
outcome. 
RESULTS 
Clinical Features 
None of the patients had a history of chickenpox as a 
child, and all had been exposed to an individual with clin- 
ical chickenpox within the last month prior to the admis- 
sion. Twelve were smokers and four recently had used 
intravenous drugs. At the time of admission, rash had 
been present for 1 to 4 days in all but one. Details of the 
medical history, clinical presentation, and outcome are 
shown in Table 1. All patients presented with a classic 
generalized maculopapular, vesicular rash more predom- 
inant on the upper body than on the lower extremities. 
Cough and dyspnea occurred in all patients, but the tim- 
ing was varied. In 11, these symptoms occurred 2 to 4 
days after the rash appeared. In three, cough and dyspnea 
occurred simultaneously with the rash, whereas in one, 
symptoms preceded the rash. 
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Table 1. Medical History, Clinical Presentation, and Outcome in 1.5 Patients with Varicella Pneumonitis 
Clinical and Laboratory Data 
Days of Arterial Blood 
IV Days of Rash before Days Platelet Gas at 
Patient Age Sex Smoking Drug Rash before Respiratory WBC Count Presentation 
Number (y) Race (M/o History User Treatment Symptoms Ho&ital Count (1 000/mm3) on Room Air 
- 
1 26 
2 30 
3 25 
4 27 
5 20 
6 32 
7 
8 
9 
10 
27 
36 
30 
23 
B 
w 
H 
A 
B 
w 
w 
w 
w 
w 
M 
F 
M 
M 
F 
M 
F 
M 
F 
F 
Yes Yes 
Yes No 
Yes Yes 
No No 
Yes No 
Yes No 
Yes No 
Yes No 
No No 
Yes No 
1 
2 
2 
3 
2 
2 
4 
4 
4 
3 
11 32 H F Yes Yes 3 
12 26 W M Yes No 4 
13 21 w F Yes Yes 3 
14 17 w F No No 3 
15 24 w F Yes No 2 
-3 
1 
1 
2 
1 
2 
4 
2 
4 
2 
2 
4 
3 
2 
2 
5 4.5 95 
5 4.8 139 
5 11.4 212 
8 9.0 141 
5 
7 
3* 
4 
5 
14 
5 
3 
5 
3 
15.1 156 
11.0 111 
5.5 84 
4.5 146 
9.0 166 
16.0 239 
9.1 208 
12.4 260 
4.8 120 
6.3 162 
4.7 119 pH = 7.46 
PaCO, = 38 mmHg 
PaO, = 69 mmHg 
0, saturation = 95% 
pH = 7.49 
PaCO, = 28 mmHg 
PaO, = 87 mmHg 
0, saturation = 97% 
pH = 7.47 
PaCO, = 31 mmHg 
PaO, = 61 mmHg 
0, saturation = 92% 
pH = 7.39 
PaCO, = 40 mmHg 
PaO, = 89 mmHg 
0, saturation = 97% 
pH = 7.52 
PaCO, = 23 mmHg 
PaO, = 86 mmHg 
0, saturation = 97% 
pH = 7.46 
PaCO, = 39 mmHg 
PaO, = 84 mmHg 
0, saturation = 96% 
pH = Not done 
PaCO, = Not done 
PaO, = Not done 
0, saturation = 88% 
pH = 7.35 
PaCO, = 45 mmHg 
PaO, = 52 mmHg 
0, saturation = 79% 
pH = Not done 
PaCO, = Not done 
PaO, = Not done 
0, saturation = 83% 
pH = 7.51 
PaCO, = 26 mmHg 
PaO, = 66 mmHg 
0, saturation = 93% 
pH = 7.43 
PaCO, = 27 mmHg 
PaO, = 53 mmHg 
0, saturation = 83% 
pH = 7.45 
PaCO, = 30 mmHg 
PaO, = 72 mmHg 
0, saturation = 94% 
pH = 7.39 
PaCO, = 36 mmHg 
PaO, = 67 mmHg 
0, saturation = 92% 
pH = 7.31 
PaCO, = 31 mmHg 
PaO, = 78 mmHg 
0, saturation = 91% 
pH = 7.44 
PaCO, = 26 mmHg 
PaO, = 76 mmHg 
0, saturation = 94% 
* = Died; B = black; W = white; H = Hispanic; A = Asian. 
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Figure 1. Admission radiograph showing bilateral and diffuse patchy 
reticulonodular interstitial infiltrates. 
Radiographic Findings 
All patients had radiographic abnormalities on the first 
chest roentgenogram. The most common (14/15) radio- 
graphic finding was a bilateral reticulonodular interstitial 
infiltrate (Figure 1). Only one patient showed a patchy 
bilateral infiltrate with plate-like atelectasis on the right. 
Hematologic Findings 
Twelve patients had a white blood cell count within nor- 
mal limits. Three had an elevated white blood cell count 
(>12,000/mm3), and eight patients were thrombocy- 
topenic (platelet count <150,000/mm3). These eight 
patients were thrombocytopenic on admission and 
platelet count returned to normal within a few days. 
Lung Function 
Arterial blood gas analysis was done on 13 patients, and 
in 7, PaO, was <SO rnmHG. In two patients, only the oxy- 
gen saturation was measured, and in both cases it was 
below 90% saturation (88% and 83%). Arterial gases 
improved with treatment in all cases except one and 
returned to normal before discharge. (Data not shown.) 
Microbiologic Findings 
Vesicular skin lesion viral cultures were performed in 11 
patients; only 3 of the 11 were positive. Respiratory secre- 
tions, sputum, or blood was cultured for virus on only 
three patients; none was positive. One sputum grew Strep- 
tococcus pneumoniae, and that patient was bacteremic 
and died of pneumonia in spite of appropriate antibiotic 
therapy. 
Treatment and Outcome 
Treatment was begun on the day of admission in all cases. 
All 15 patients received intravenous acyclovir at a dose 
of 10 mg/kg every 8 hours for a 7- to lo-day course. 
Patients with rapid clinical improvement (i.e., no new 
lesions and with old lesions crusted) on intravenous acy- 
clovir were switched to oral acyclovir at a dose of 800 
mg five times daily to complete the 7- to lo-day course. 
Three patients received antibiotics with the acyclovir. 
These included patient No. 8, who died of bacterial pneu- 
monia during hospitalization. The other 14 patients recov- 
ered completely and were discharged without comorbid 
conditions. 
The patient who died of bacterial pneumonia had a 
history of exposure to chickenpox 2 to 4 weeks before 
presentation, had no history of chickenpox as a child, 
and was a heavy smoker. He developed shortness of 
breath, cough, and fever 2 days after the appearance of 
the rash. Some of the skin vesicles showed central hem- 
orrhage. His white blood cell count was within the nor- 
mal range, but the platelet count was 84,000/mm3 on 
presentation. Arterial blood gases on admission were: pH, 
7.35; PaCO,, 45 mmHg; PaO,, 52 mmHg; and 0, saturation, 
79%. The patient did not respond to oxygen therapy. His 
PaO, decreased to 31 and 0, saturation was 53% on six 
liters of oxygen. On the second day after admission, he 
continued to deteriorate and was started on hydrocorti- 
sane, 100 mg every 8 hours. On the third day, sputum 
Gram stain showed less than 10 epithelial cells, more 
than 25 polymorphonuclear cells, and many gram-posi- 
tive cocci in pairs and chains. A repeat chest roentgeno- 
gram showed new right upper and middle lobe 
consolidations. Hydrocortisone was stopped, and the 
patient was started on nafcillin. Subsequently, sputum and 
blood culture grew Spneumoniae, and vancomycin was 
added to nafcillin, but the patient died within 24 hours 
of antibiotic treatment. 
DISCUSSION 
Although less than 2% of varicella infections occur in 
adults, varicelIa is often a serious infection in an adult: 28% 
of deaths from varicella occur in this age group. The esti- 
mated risk of death due to varicella is 2/100,000 in 
healthy children versus 50/100,000 in healthy adults.* 
Varicella pneumonitis is the most frequent serious com- 
plication of adult primary varicella and is the major cause 
of death in this age group. Without treatment, the mor- 
tality rate in varicella pneumonitis has been reported to 
be 10 to 30% in otherwise healthy adults and 41% in 
pregnant women.2*5,6 In the present study, 7% (l/15) of 
the patients died, and that death was most probably due 
to overwhelming bacteremic pneumococcal pneumonia. 
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Clinical presentation of varicella pneumonitis in this 
study was identical to that reported by Triebwasser et al.’ 
In the present study, symptoms of pneumonitis developed 
within 1 to 4 days after the onset of a rash. Cardinal symp- 
toms and signs of varicella pneumonitis were fever, cough, 
dyspnea, tachypnea, and hypoxia. Chest examination was 
usually positive for bronchial breath sounds or wheezes. 
Thirteen of fifteen patients had abnormalities on chest 
examination. Temperature was often elevated (1 l/15) and 
preceded respiratory symptoms. All patients became 
afebrile within 3 to 5 days of presentation. 
In the present study, 45% of patients presented with 
thrombocytopenia, and platelet count returned to nor- 
mal without steroid treatment. The reduction in the 
platelets was mild and associated with no hemorrhagic 
phenomenon. It was probably due to the direct effect of 
the virus, which causes shortening of platelet survival, 
rather than to immunologic mechanisms, which are usu- 
ally operative after the acute stage.’ This observation is 
consistent with, but not identical to that in a previous 
report,* which reported thrombocytopenia in as high as 
83% (5/6) of patients with varicella penumonia. 
Smoking appears to be a risk factor for the devel- 
opment of pneumonitis. Ellis et al concluded that chick- 
enpox pneumonitis occurred only in smokers.9 In the 
present report, 80% of patients were smokers. The appar- 
ent adverse effect of smoke or other components of 
tobacco may be on the pulmonary macrophage, making 
it an easier target for virus replication and infection.1° 
Similar observations have been made in influenza due to 
HlNl, in which young adults who smoke are more prone 
to severe illness.” 
Acyclovir is a deoxyguanosine analogue that provides 
clinically useful antiviral therapy against herpes viruses. 
Among herpes viruses, acyclovir is more potent against 
herpes simplex type I and type II than varicella zoster 
virus and less active against cytomegalovirus and Epstein- 
Barr virus.12,13 Acyclovir has been used successfully for 
herpes simplex type I and type II infection in immuno- 
competent and immunocompromised patients.14-‘l Intra- 
venous acyclovir currently is the treatment of choice for 
varicella zoster, both localized and disseminated, in 
immunocompromised hosts.22,23 Federz4 in an unblinded 
study, showed that oral acyclovir is effective for treatment 
of adult chickenpox, especially if started within the first 
24 hours of exanthem. 
The role of acyclovir treatment for varicella zoster 
infection in healthy adults has been documented in con- 
trolled studies, but the low frequency of serious compli- 
cations of varicella (pneumonitis and encephalitis) 
precluded any evaluation of the possible effects of acy- 
clovir in this studyz5 
In the retrospective study reported here, intravenous 
acyclovir was used at a dose of 10 mg/kg every 8 hours, 
in all patients. The choice of acyclovir relies on case 
reports of adults with varicella pneumonitis and on trials 
of acyclovir treatment of localized and disseminated vari- 
cella infection in immunocompromised hosts.2,21,22,26 Four- 
teen of fifteen adult patients with varicella pneumonia 
showed clinical improvement within 48 hours of starting 
acyclovir and recovered completely without any com- 
plication or side effect of the drug. This observation 
extends and reaffirms the results reported by Haake et 
aLz6 who concluded that early initiation of intravenous 
acyclovir for varicella pneumonia is associated with clin- 
ical improvement. 
In the absence of controlled clinical trials to answer 
this question definitively, acyclovir is a well-tolerated and 
potentially efficacious drug for treatment of varicella 
pneumonitis. Steroids do not appear to be warranted for 
varicella pneumonitis in adults treated with acyclovir. 
The rates of morbidity and mortality of varicella pneu- 
monia in immunocompetent adults treated with acyclovir 
may be lower than rates reported prior to the availabil- 
ity of acyclovir. 
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